Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients | Future Oncology
Multiple Myeloma Treatment Options | First Line Therapy
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
VRd Lite 療法
Treating Frail and Transplant-Ineligible Patients With MM
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Multiple Myeloma Treatment Options | First Line Therapy
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis | SpringerLink
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
Cancers | Free Full-Text | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Induction Therapy for Newly Diagnosed Multiple Myeloma
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review - McCaughan - 2022 - British Journal of Haematology - Wiley Online Library
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Cancers | Free Full-Text | 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
Mohamad Mohty on Twitter: "VRD lite is a key player in my opinion @Mohty_EBMT #ASH17 https://t.co/eHqUTtQwMU" / Twitter
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Understanding the VRd Regimen for Newly Diagnosed Myeloma by International Myeloma Foundation - Issuu
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
